RNAC logo

CARTESIAN THERAPEUTICS INC

RNACNASDAQ
🏆 #3590 by market capEarnings Nov 4US Equity
$6.75▲ $0.04 (+0.60%)
Market closed · at close
🔔
Track RNAC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.6%
7d▲ 9.0%
14d▲ 7.7%
30d▼ 6.9%
ytd▼ 6.2%
1y▼ 16.7%
🏦Market Cap
$204M
Small Cap
📈Revenue Growth (YoY)
-20.7%
Declining
📊Gross Margin
—
💵FCF Margin
422.1%
Strong
⚖️P/S Ratio
115.6x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$6.66 – $6.86
52-Week Range
$5.60 – $11.00
Volume (shares)
5,468
Avg Volume (shares)
—
Shares Outstanding
30.3M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
115.6x
EPS (TTM)
$-5.87
Dividend Yield
—
Dilution (1yr)
+0.3%
RNAC logo

CARTESIAN THERAPEUTICS INC

RNAC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3M▼ −92.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$87M▲ +97.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$79M▲ +142.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
26.0M▲ +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$112M▼ −$86M YoY
StockOtter · stockotter.space

About CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
13 analysts
Strong Buy5
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.